Results 201 to 210 of about 31,381 (233)
RETRACTION: Circular RNA circFBXO11 Modulates Hepatocellular Carcinoma Progress and Oxaliplatin Resistance Through miR-605/FOXO3/ABCB1 Axis. [PDF]
J Cell Mol Medeuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The cellular pharmacology of oxaliplatin resistance
European Journal of Cancer, 2002Oxaliplatin is a third generation platinum compound that differs from cisplatin and carboplatin in having a broader spectrum of antitumour activity. Molecular studies suggest that oxaliplatin adducts are recognised and processed differently than those produced by the earlier generation Pt-containing drugs.
Stephen Howell, S B Howell, M Mishima
exaly +3 more sources
Gastric Cancer, 2021
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs.
Kenji Harada +13 more
openaire +2 more sources
In vitro studies on the mechanisms of oxaliplatin resistance
Cancer Chemotherapy and Pharmacology, 2001We have previously reported that elevation of glutathione mediated by gamma-glutamyl transpeptidase is one mechanism of oxaliplatin resistance. This study explored other potential oxaliplatin resistance mechanisms with two aims: (1) to identify the differences between cisplatin and oxaliplatin in terms of drug accumulation, DNA-Pt adduct formation and ...
Suzanne Hector +2 more
exaly +3 more sources
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review [PDF]
Cancer Treatment Reviews, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer.
Nick Pavlakis, Ross Davey
exaly +6 more sources
JBIC Journal of Biological Inorganic Chemistry, 2017
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
Oxaliplatin is the backbone of chemotherapy for advanced colorectal cancer and undergoes clinical trials for treatment of other tumour entities. However, acquired resistance is a major hurdle. Confocal microscopy is a useful tool to get an insight into the mechanisms of resistance but it requires fluorescent compounds. This work describes the synthesis
Kalayda, Ganna V. +3 more
openaire +2 more sources
MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells
Cell Biochemistry and Biophysics, 2020We aimed to understand the molecular mechanism underlying the incidence of Oxaliplatin resistance in colorectal cancer. The Oxaliplatin-resistant (OR) HT29 colorectal cell line was established by long-term exposure to Oxaliplatin. Cell viability and proliferation were determined by the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide and ...
Zhicheng Zhao, Guojing Zhang, Weidong Li
openaire +2 more sources
Clinical Cancer Research, 2007
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett +6 more
openaire +2 more sources
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett +6 more
openaire +2 more sources
Txr1: an important factor in oxaliplatin resistance in gastric cancer
Medical Oncology, 2013Oxaliplatin-based chemotherapy is the main treatment regimen for gastric cancer (GC), but can fail because of drug resistance. We investigated the role of a recently identified drug-resistance gene, taxol-resistant gene 1 (Txr1), in oxaliplatin resistance. A retrospective study based on banked tissue was carried out.
Jingtao, Bi +8 more
openaire +2 more sources
The involvement of Aurora‐A and p53 in oxaliplatin‐resistant colon cancer cells
Journal of Cellular Biochemistry, 2023AbstractResistance to chemotherapy is the deadlock in cancer treatment. In this study, we used wild‐type LOVO (LOVOWT), a human colon cancer cell line, and the oxaliplatin‐resistant sub‐clone LOVOOR cells to investigate the molecular mechanisms of the development of drug resistance in colon cancer.
Mei‐Chih Chen +7 more
openaire +2 more sources